Session Information
Date: Tuesday, November 10, 2026
Title: (1977-1995) Systemic Lupus Erythematosus - Translational Models and Mechanisms Poster C
Session Type: Poster Session C
Session Time: 10:30AM-12:30PM
Background/Purpose: Neutrophils are increasingly recognized as drivers of systemic lupus erythematosus (SLE), and glucocorticoids such as methylprednisolone (MP) are widely used to suppress inflammation. While profiling neutrophil transcriptomes in a patient with SLE undergoing CD19 chimeric antigen receptor (CAR) T-cell therapy, we observed that in vivo pulse MP produced minimal change in the disease-specific neutrophil transcriptomic signature, suggesting steroids may not broadly deactivate neutrophils. We therefore examined how MP modulates neutrophil transcription, inflammatory cytokine secretion and directed migration in healthy and SLE donors.
Methods: Neutrophils were isolated by negative selection from healthy controls (HC) and patients with SLE, including subgroups receiving anifrolumab or belimumab (Table 1). All patients with SLE met at least 4 of the 2019 EULAR/ACR classification criteria. For functional assays, neutrophils were cultured for 18 hours under four matched conditions: diluted DMSO vehicle, MP alone (22.7 µM), lipopolysaccharide (LPS) alone (100 ng/ml), or LPS plus MP; TNF, CCL3, and IL-8 were measured in supernatants, and migration toward IL-8 was assessed by 1-hour transwell assay as fold change (FC) relative to the no-chemoattractant condition. Separately, neutrophils from HC and patients with SLE were treated ex vivo with MP (22.7 µM, 2 hours) and profiled by bulk RNA sequencing. Cohorts partially overlapped.
Results: MP induced classical GC early-response genes (e.g. FKBP5, TSC22D3, KLF9, DUSP1, NFKBIA) in both HC and SLE neutrophils, confirming an intact GC transcriptional response. LPS robustly induced TNF, CCL3, and IL-8 secretion in both HC and SLE, whereas MP alone did not (Figure 1). Co-treatment with MP markedly reduced LPS-induced secretion of all three cytokines across groups. In contrast, MP increased IL-8-directed migration in every group tested (Figure 2). In HC, median migration rose from FC ~2 with vehicle to ~11 with MP; in patients with SLE, from ~1.6 to ~6.5. Neutrophils from SLE patients receiving anifrolumab or belimumab also showed MP-enhanced migration, though of lesser magnitude (median FC ~3-4). Additionally, LPS stimulation alone did not promote migration, whereas adding MP to LPS increased it in HC and patients with SLE.
Conclusion: MP engaged the classical GC transcriptional program in neutrophils and suppressed LPS-induced inflammatory cytokine secretion, the expected glucocorticoid response, yet paradoxically enhanced directed migration, in both healthy individuals and patients with SLE. Rather than broadly deactivating neutrophils, MP appears to reprogram them, dampening cytokine output while priming a pro-migratory phenotype. These findings have potential implications for infection risk and tissue injury during steroid therapy in SLE.
Table 1. Demographic and clinical characteristics of study participants. Values are median (Q1, Q3), number, or percentage, as indicated.
Figure 1. Methylprednisolone suppresses LPS-induced neutrophil cytokine secretion. Neutrophils from healthy controls (HC), patients with SLE, and an anifrolumab-treated SLE subgroup (SLE.Anifrolumab) were cultured for 18 hours with diluted DMSO vehicle, methylprednisolone alone (MP, 22.7 µM), lipopolysaccharide alone (LPS, 100 ng/ml), or LPS plus MP (MP_LPS). Concentrations of (A) IL-8, (B) CCL3, and (C) TNF were measured in culture supernatants (pg/ml). Boxes show the median and interquartile range.
Figure 2. Methylprednisolone enhances IL-8-directed neutrophil migration in health and SLE. Neutrophils were isolated by negative selection from healthy controls (HC) and patients with systemic lupus erythematosus (SLE), including subgroups receiving anifrolumab (SLE.Anifrolumab) or belimumab (SLE.Belimumab), and cultured for 18 hours with diluted DMSO vehicle, methylprednisolone alone (MP, 22.7 µM), lipopolysaccharide alone (LPS, 100 ng/ml), or LPS plus MP (MP_LPS). Cells were then assessed for migration toward IL-8 in a 1-hour transwell assay. Migration is expressed as fold change (FC) relative to the no-chemoattractant condition (no_IL8, FC = 1). Boxes show the median and interquartile range.
To cite this abstract in AMA style:
Hu G, Dehdashtian E, Whiteman L, Islam M, Gallucci S, Caricchio R. A Pro-Migratory Paradox: Methylprednisolone Dampens Cytokine Secretion yet Enhances Neutrophil Migration in Health and Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/a-pro-migratory-paradox-methylprednisolone-dampens-cytokine-secretion-yet-enhances-neutrophil-migration-in-health-and-systemic-lupus-erythematosus/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pro-migratory-paradox-methylprednisolone-dampens-cytokine-secretion-yet-enhances-neutrophil-migration-in-health-and-systemic-lupus-erythematosus/
